Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Philip Newlin (NPI 1124055942)

Field	Value
Entity Type	Individual
Organization	Philip Newlin
Address	818 N Carriage Pkwy
City	Wichita
State	KS
ZIP	67208
Taxonomy	Pediatrics Physician
NPI Enumerated	June 27, 2006

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider’s book of business is effectively single‑payer: total Medicare revenue is $2M and there is no Medicaid billing on file. The provider’s Medicare portfolio is highly concentrated, with the precomputed top‑3 Medicare codes accounting for 81.9% of total Medicare revenue, indicating limited revenue diversity across payers.

The top revenue drivers are nuclear medicine and PET imaging: A9595 ($700.3K, 36.4%), 78815 ($574.5K, 29.8%), and A9596 ($301K, 15.6%) together dominate receipts and point to an operation centered on radiopharmaceutical diagnostics and combined PET/CT studies. Those three codes’ descriptions (piflufolastat f‑18, PET/CT imaging, and gallium ga‑68 gozetotide) align with a specialty imaging service line focused on oncologic diagnostic imaging rather than broad primary care.

Revenue concentration is extreme within Medicare: the single code A9595 represents $700.3K (36.4%) of the $2M Medicare total, while the top three codes together make up 81.9% of Medicare revenue. This level of concentration means changes in utilization, reimbursement, or access for these specific radiopharmaceuticals or PET/CT services would materially affect the provider’s Medicare income.

Competitive standing on key PET items is nationally prominent: A9595 ranks #12 of 528 providers nationally (98th percentile; notably above typical national volume for this code) and 78815 ranks #195 of 6566 providers nationally (97th percentile; notably above typical national volume for this code). By contrast, A9596 ranks #18 of 168 providers nationally (90th percentile; typical, unremarkable volume), indicating the provider is a major national participant for some radiopharmaceuticals but more of a typical user for others.

Beyond the PET radiopharmaceuticals, the claim mix includes a broad set of imaging and image‑guided procedure codes (for example, mammography/tomosynthesis codes 77067/77063/77066 and MRI/CT codes such as 70553, 74177, 71250). Each of these other codes contributes at single‑digit percent shares of overall Medicare revenue, showing some service breadth that supplements—but does not replace—the PET/nuclear medicine revenue base.

There are notable high‑volume signals in non‑PET procedures as well: breast biopsy codes 19081 and 19083 appear with elevated standing (19081 ranks #37 of 1707 providers nationally, 98th percentile; 19083 ranks #195 of 3438 providers nationally, 94th percentile), suggesting the provider performs a meaningful volume of image‑guided breast procedures in addition to PET imaging. These non‑PET high percentiles point to ancillary procedure capacity that could be relevant for breast‑imaging networks or bundled service discussions.

The NPI has been enumerated since 2006‑06‑27 (~20 years ago), indicating a long tenure in Medicare billing which supports operational stability in the Medicare stream. Given the age of the enrollment and the concentrated Medicare revenue, analysts should treat this as an established imaging/billing entity with legacy Medicare relationships rather than a new entrant.

For payer strategy and contracting, the combination of no Medicaid billing on file and the 81.9% concentration in three PET/nuclear codes suggests focused negotiation opportunities and capacity risk: payers contracting in this market should note the provider’s dependence on a small set of high‑value, high‑volume diagnostic codes and plan networks or utilization management accordingly.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

69 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	1,460	$480	$700.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	540	$1,060	$574.5K
A9596	Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie	390	$760	$301K
77067	The provider takes two X–ray views of each breast for routine screening and may use specially designed computer software to help identify any potential abnormalities within the images; the software…	740	$80	$61.3K
A9592	Copper cu-64, dotatate, diagnostic, 1 millicurie	70	$640	$46.4K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	300	$90	$28.4K
70553	In this procedure, the provider performs a magnetic resonance imaging, or MRI, study of the brain including the brain stem. He performs this procedure without using contrast material. He then follows…	180	$140	$24.5K
74177	The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs.	130	$150	$19.1K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	20	$1,070	$18.3K
19081	Under stereotactic guidance, the provider takes breast tissue percutaneously from a single lesion for biopsy. He may place a localization device at the same time.	50	$370	$16.8K

Showing 1–10 of 69

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 69 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Philip Newlin — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

69 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9595	1	10	500	$480	$291.6K
A9596	1	10	300	$780	$234.9K
78815	2	90	60	$490	$56K
A9592	1	10	70	$640	$46.4K
A9552	4	20	130	$140	$21.7K
77067	31	310	100	$60	$16.9K
78816	18	20	20	$390	$16.5K
74177	110	200	140	$80	$13.2K
70553	14	120	50	$110	$9K
77063	28	310	100	$30	$8.3K

Showing 1–10 of 69

Related Providers

Other providers that share a Tax Identification Number (TIN) with Philip Newlin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ascension Medical Group Via Christi, PA	KS	Multi-Specialty Clinic/Center	$0	$21.2M
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Thomas Finley	OK	Ophthalmology Physician	$4.8M	$0
Daniel Feiler	KS	Ophthalmology Physician	$4.8M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Stephen Wiles	MO	Ophthalmology Physician	$4.4M	$0

Nearby Providers

Other providers in the same ZIP code as Philip Newlin, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
County Of Sedgwick	KS	Case Manager/Care Coordinator	$0	$15.5M
County Of Sedgwick	KS	Psychiatry Physician	$0	$5.9M
Great Plains Dental Group, LLC	KS	General Practice Dentistry	$0	$5.8M
Mental Health America Of South Central Kansas, Inc.	KS	Community/Behavioral Health Agency	$0	$5.7M
Kidspace Pediatric Dentistry,p.a	KS	Pediatric Dentistry	$0	$4.4M
Cerebral Palsy Research Foundation Of Kansas, Inc	KS	Non-emergency Medical Transport (VAN)	$0	$4.3M
Nassim Nabbout	KS	Hematology & Oncology Physician	$4.2M	$0
Phu Truong	KS	Hematology & Oncology Physician	$4.1M	$0
Grace Home Care, LLC	KS	Home Health Agency	$0	$4M
Joseph Moore	KS	Hematology & Oncology Physician	$3.6M	$0

Philip Newlin — Billing Profile & Reimbursement Data

Sign up for Philip Newlin — Billing Profile & Reimbursement Data policy alerts

Philip Newlin — Billing Profile & Reimbursement Data

Sign up for Philip Newlin — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References